Status:
COMPLETED
ARQ 501 in Subjects With Cancer
Lead Sponsor:
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using ...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
- ECOG performance status greater than or equal to 1
- Life expectancy greater than three months
- Acceptable pretreatment clinical laboratory results
- Exclusion Criteria
- Subjects who have had chemotherapy or radiotherapy within 4 weeks
- Subjects receiving any other investigational agents
- Subjects with known untreated brain metastases
- Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD")
- Subjects with uncontrolled intercurrent illnesses
- Pregnant women
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00075933
Start Date
September 1 2003
End Date
January 1 2007
Last Update
April 28 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana Farber/Partners CancerCare Inc
Boston, Massachusetts, United States, 02115
2
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75201